Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk A/S - share repurchase programme
09:18am, Monday, 08'th Jul 2024
Bagsværd, Denmark, 08 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
Copper, Gold Stocks Sparkle, Among 5 Leaders Near Buy Points
08:00am, Saturday, 06'th Jul 2024
Southern Copper and gold stock Agnico eagle surged above early buy points on hopeful signs for U.S. and China policy.
Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector
09:43am, Friday, 05'th Jul 2024
Danish drugmaker Novo Nordisk has been reprimanded by UK regulators for failing to disclose fees and expenses paid to individuals and organisations in Britain amounting to about 7.8 million pounds ($9
Is It Too Late to Buy Novo Nordisk Stock?
05:50am, Friday, 05'th Jul 2024
Novo Nordisk's valuation is high, and the U.S. patent for semaglutide expires in early 2026. However, the drugmaker has a promising pipeline that could drive growth for years to come.
Novo Nordisk shares drop as study links drugs to vision loss
10:00am, Thursday, 04'th Jul 2024
Novo Nordisk (NYSE:NVO) shares have dropped by close to 4% this week, shedding more than £350 billion from its market cap, after a study suggested there may be a link between its blockbuster weight
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
09:20am, Thursday, 04'th Jul 2024
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Novo Nordisk shares shrug off concerns over study linking weight loss drugs to rare eye condition
06:23am, Thursday, 04'th Jul 2024
Blockbuster weight loss drugs such as Wegovy and Ozempic may be associated with a rare eye condition, according to a new study released Wednesday. A Novo Nordisk spokesperson said there were "key meth
Weight-loss drugs linked to rare vision loss: Harvard study
05:40pm, Wednesday, 03'rd Jul 2024
Novo Nordisk (NVO) and Eli Lilly (LLY) shares dip in reaction to a Harvard study that found GLP-1 weight-loss drugs Ozempic and Wegovy could be linked to rare cases of vision loss. Yahoo Finance healt
Using Ozempic Or Wegovy Could Raise Risk For Rare Form Of Blindness, Study Suggests
01:28pm, Wednesday, 03'rd Jul 2024
People who use Ozempic or Wegovy for treating obesity or Type 2 diabetes may have an increased risk of developing a rare form of blindness, according to a study published Wednesday in the journal JAMA
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
12:35pm, Wednesday, 03'rd Jul 2024
Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.
The 7 Best Stocks to Buy in July 2024
11:52am, Wednesday, 03'rd Jul 2024
The first half of the trading year is in the books, and by all accounts, it was a resounding success. The benchmark S&P 500 index rose 15% from January through the end of June, hitting all-time highs
Wegovy, Ozempic linked with sight-threatening eye disorder in study
11:30am, Wednesday, 03'rd Jul 2024
Patients using Novo Nordisk's wildly popular weigh-loss drug Wegovy and its similar medicines for type 2 diabetes may be at increased risk for a sight-threatening eye condition, according to data from
Novo Nordisk and Eli Lilly Slide as Biden Blasts Weight-Loss Drug Prices
05:01pm, Tuesday, 02'nd Jul 2024
Novo Nordisk (NVO) American depositary receipts (ADRs) and Eli Lilly (LLY) shares lost ground Tuesday after U.S. President Joe Biden and Senator Bernie Sanders called out the companies in an op-ed for
Weighing the Future of Weight Loss Drugs
01:44pm, Tuesday, 02'nd Jul 2024
How are obesity drugs impacting other industries? Julia Angeles discusses the future of weight loss drugs.
Why Novo Nordisk Stock Is Slipping Today
11:54am, Tuesday, 02'nd Jul 2024
A USA Today op-ed from President Joe Biden and Sen. Bernie Sanders criticized Novo Nordisk.
